TY - JOUR T1 - The efficacy of vaccines in the context of SARS-CoV-2 and its variants: Role of Spatio-temporal boundary JF - medRxiv DO - 10.1101/2021.07.19.21260758 SP - 2021.07.19.21260758 AU - Durbar Roy AU - Dipshikha Chakravortty AU - Saptarshi Basu Y1 - 2021/01/01 UR - http://medrxiv.org/content/early/2021/07/26/2021.07.19.21260758.abstract N2 - The preference for a COVID-19 vaccine, among many available, may be difficult for common people and normally relies on efficacy values reported from clinical trials. Vaccine efficacy depends on statistical data from primary and secondary endpoints of a trial. This study provides a time-varying mathematical framework that compares two vaccines of contrasting efficacy (Pfizer-BioNTech and AstraZeneca-Oxford) using hypothetical trials with real-world data. Modeling shows that efficacies can fluctuate depending on the prevailing infection rate and demographics. The efficacy of AstraZeneca-Oxford can become comparable and even better than Pfizer-BioNTech, depending on the region and time of the clinical trials. We also introduce an idea of composite efficacy considering multi-variants and show that the efficacy of various vaccines shows differential sensitivity to the delta variant rampant in India.Competing Interest StatementThe authors have declared no competing interest.Clinical Protocols https://www.overleaf.com/project/60f3f4972d7eee548b39b610 Funding StatementNAAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:NAAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData available within the manuscript https://www.overleaf.com/project/60f3f4972d7eee548b39b610 ER -